NIH-funded discovery uses common antifungal drug to improve lungs’ ability to fight infection.

Researchers say a widely-used antifungal drug may hold promise for treating people with cystic fibrosis, a life-threatening genetic disorder that causes serious damage to the lungs. In studies using human cells and animals models, the researchers found that the medication, called amphotericin, helps lung cells function in a way that could make it easier for patients to fight chronic bacterial lung infections that are a hallmark of the disease. The findings from the study, which was supported in part by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, will appear in the journal Nature.

Related posts:

  1. Medicare Card, Cardiac bypass surgery superior to non-surgical procedure for adults with diabetes and heart disease Medicare Card, Cardiac bypass surgery superior to non-surgical procedure for adults with diabetes and heart disease...
  2. Medicare Card, NIH urges women to protect their heart health Medicare Card, NIH urges women to protect their heart health ...
  3. Medicare Card, NIH launches largest clinical trial focused on HIV-related cardiovascular disease Medicare Card, NIH launches largest clinical trial focused on HIV-related cardiovascular disease...
  4. Medicare Card – Lower Risk of Heart Disease Linked to Light physical activity in older women Light physical activity such as gardening, strolling through a park, and folding clothes might be enough to significantly lower the risk of cardiovascular disease among women 63 and older, a new study has found. This kind of activity, researchers said, appears to reduce the risk of cardiovascular disease events such as stroke or heart failure […]...
  5. Medicare Card, Common treatment for patients with chronic, progressive lung disease found to be ineffective Medicare Card, Common treatment for patients with chronic, progressive lung disease found to be ineffective...
  6. Medicare Card, Adults stop anti-rejection drugs after partial stem-cell transplant reverses sickle cell disease NIH trial success suggests a new treatment option for older, sicker patients.   Half of patients in a trial have safely stopped immunosuppressant medication following a modified blood stem-cell transplant for severe sickle cell disease, according to a study in the July 1 issue of the Journal of the American Medical Association External Web Site Policy. […]...
  7. NIH-funded study finds new possible risk factor of heart disease, Medicare NIH-funded study finds new possible risk factor of heart disease, Medicare...
  8. Medicare Card, Protein linked to increased risk of heart failure and death in older adults Medicare Card, Protein linked to increased risk of heart failure and death in older adults...
  9. Medicare Card, Long-term oxygen treatment does not benefit some COPD patients Medicare Card, Long-term oxygen treatment does not benefit some COPD patients ...
  10. Medicare Card, Infants born with a severely underdeveloped heart Medicare Card, Infants born with a severely underdeveloped heart...
  11. MedicareCard urges women to protect their heart health As part of American Heart Month, on Wednesday, Feb. 8, 2012, the National Heart, Lung, and Blood Institute’s (NHLBI’s) The Heart Truth campaign, with the support of the Foundation for the National Institutes of Health (FNIH), will showcase its signature event, the Red Dress Collection 2012 at Mercedes-Benz Fashion Week in New York City....
  12. Concentrated saline therapy not effective in young children with cystic fibrosis Inhaling concentrated saline (salt water) mist does not reduce how often infants and young children with cystic fibrosis (CF) need antibiotics for respiratory symptoms, according to findings from a clinical trial sponsored by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health....
  13. Medicare, NHLBI launches program on early cystic fibrosis lung disease Researchers will study pre-symptomatic lung disease in infants and young children with cystic fibrosis (CF), under a new grant program of the National Heart, Lung, and Blood Institute (NHLBI). Results could reveal how CF develops, which in turn could lead to interventions that delay or prevent disease progression. The studies also could provide critical information […]...
  14. Medicare Card, New medication shows promise against liver fibrosis in animal studies Medicare Card, New medication shows promise against liver fibrosis in animal studies...
  15. Commonly used three-drug regimen for idiopathic pulmonary fibrosis found harmful The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, has stopped one arm of a three arm multi-center, clinical trial studying treatments for the lung-scarring disease idiopathic pulmonary fibrosis (IPF) for safety concerns....